Drug Profile
Erdafitinib - Janssen Pharmaceutica
Alternative Names: BALVERSA; G-024; JNJ-42756493; JNJ-493; TAR-210Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Astex Therapeutics; Newcastle University
- Developer Genentech; Janssen Pharmaceutica; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; University of Washington; Vanderbilt-Ingram Cancer Center
- Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Urogenital cancer
- Phase II Bladder cancer; Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
- Phase I/II Liver cancer
- No development reported Breast cancer; Lymphoma
Most Recent Events
- 20 Mar 2024 Janssen Research & Development plans phase-III MoonRISe-1 trial for Bladder cancer in Czech republic (intravesicular) , (NCT06319820)
- 15 Mar 2024 Janssen Research & Development completes a phase IIa trial for Urogenital cancer, Cholangiocarcinoma, Gastric cancer, Non-small cell lung cancer and Oesophageal cancer (Second-line or greater therapy, Late-stage disease) in Taiwan, China and South Korea (NCT02699606)
- 19 Jan 2024 The US FDA grants full approval for erdafitinib for Urogenital cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)